Novel drugs for hypertension and heart failure: Struggling for a place under the sun

Charles Faselis, Chrysoula Boutari, Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Peter Kokkinos

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions. METHODS: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives. RESULTS: LCZ696 seems a very promising antihypertensive agent, that additionally generates clinically meaningful benefits in patients with heart failure with reduced injection fraction and raises expectations for the management of patients with heart failure with preserved ejection fraction. Finerenone aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria. First available data are very promising for the efficacy of the drug, while it provides a better safety profile than current mineralocorticoid antagonists. CONCLUSION: LCZ696 and finerenone are two novel drugs for the management of arterial hypertension and heart failure. First available data point toward important clinical benefits from their use. Future large trials further investigating the cardiovascular profile of these agents will establish the use of these drugs.

Original languageEnglish (US)
Pages (from-to)1540-1550
Number of pages11
JournalCurrent Pharmaceutical Design
Volume23
Issue number10
DOIs
StatePublished - Mar 1 2017

Fingerprint

Solar System
Mineralocorticoid Receptor Antagonists
Heart Failure
Hypertension
Pharmaceutical Preparations
Medication Therapy Management
Cardiovascular Agents
Neprilysin
Albuminuria
Angiotensin Receptor Antagonists
Antihypertensive Agents
Safety
Injections
BAY 94-8862
LCZ 696

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Keywords

  • Albuminuria
  • Diabetic kidney disease
  • Finerenone
  • Heart failure
  • Hypertension
  • LCZ696
  • Mineralocorticoid receptor antagonists
  • Neprilysin

Cite this

Faselis, Charles ; Boutari, Chrysoula ; Doumas, Michael ; Imprialos, Konstantinos ; Stavropoulos, Konstantinos ; Kokkinos, Peter. / Novel drugs for hypertension and heart failure : Struggling for a place under the sun. In: Current Pharmaceutical Design. 2017 ; Vol. 23, No. 10. pp. 1540-1550.
@article{be9ed4eb7e6941c2bf0b1f2a005b39e2,
title = "Novel drugs for hypertension and heart failure: Struggling for a place under the sun",
abstract = "Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions. METHODS: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives. RESULTS: LCZ696 seems a very promising antihypertensive agent, that additionally generates clinically meaningful benefits in patients with heart failure with reduced injection fraction and raises expectations for the management of patients with heart failure with preserved ejection fraction. Finerenone aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria. First available data are very promising for the efficacy of the drug, while it provides a better safety profile than current mineralocorticoid antagonists. CONCLUSION: LCZ696 and finerenone are two novel drugs for the management of arterial hypertension and heart failure. First available data point toward important clinical benefits from their use. Future large trials further investigating the cardiovascular profile of these agents will establish the use of these drugs.",
keywords = "Albuminuria, Diabetic kidney disease, Finerenone, Heart failure, Hypertension, LCZ696, Mineralocorticoid receptor antagonists, Neprilysin",
author = "Charles Faselis and Chrysoula Boutari and Michael Doumas and Konstantinos Imprialos and Konstantinos Stavropoulos and Peter Kokkinos",
year = "2017",
month = "3",
day = "1",
doi = "10.2174/1381612823666170206154706",
language = "English (US)",
volume = "23",
pages = "1540--1550",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

Novel drugs for hypertension and heart failure : Struggling for a place under the sun. / Faselis, Charles; Boutari, Chrysoula; Doumas, Michael; Imprialos, Konstantinos; Stavropoulos, Konstantinos; Kokkinos, Peter.

In: Current Pharmaceutical Design, Vol. 23, No. 10, 01.03.2017, p. 1540-1550.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Novel drugs for hypertension and heart failure

T2 - Struggling for a place under the sun

AU - Faselis, Charles

AU - Boutari, Chrysoula

AU - Doumas, Michael

AU - Imprialos, Konstantinos

AU - Stavropoulos, Konstantinos

AU - Kokkinos, Peter

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions. METHODS: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives. RESULTS: LCZ696 seems a very promising antihypertensive agent, that additionally generates clinically meaningful benefits in patients with heart failure with reduced injection fraction and raises expectations for the management of patients with heart failure with preserved ejection fraction. Finerenone aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria. First available data are very promising for the efficacy of the drug, while it provides a better safety profile than current mineralocorticoid antagonists. CONCLUSION: LCZ696 and finerenone are two novel drugs for the management of arterial hypertension and heart failure. First available data point toward important clinical benefits from their use. Future large trials further investigating the cardiovascular profile of these agents will establish the use of these drugs.

AB - Backgound: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions. METHODS: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives. RESULTS: LCZ696 seems a very promising antihypertensive agent, that additionally generates clinically meaningful benefits in patients with heart failure with reduced injection fraction and raises expectations for the management of patients with heart failure with preserved ejection fraction. Finerenone aims to be safer than current aldosterone antagonists and has been so far tested in patients with heart failure and in patients with albuminuria. First available data are very promising for the efficacy of the drug, while it provides a better safety profile than current mineralocorticoid antagonists. CONCLUSION: LCZ696 and finerenone are two novel drugs for the management of arterial hypertension and heart failure. First available data point toward important clinical benefits from their use. Future large trials further investigating the cardiovascular profile of these agents will establish the use of these drugs.

KW - Albuminuria

KW - Diabetic kidney disease

KW - Finerenone

KW - Heart failure

KW - Hypertension

KW - LCZ696

KW - Mineralocorticoid receptor antagonists

KW - Neprilysin

UR - http://www.scopus.com/inward/record.url?scp=85020854415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020854415&partnerID=8YFLogxK

U2 - 10.2174/1381612823666170206154706

DO - 10.2174/1381612823666170206154706

M3 - Review article

C2 - 28176630

AN - SCOPUS:85020854415

VL - 23

SP - 1540

EP - 1550

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 10

ER -